![]() The final estimate of an intervention’s effectiveness relative to any other in that domain is generated from patients who could have been randomized to either.ĮTable 1. ![]() ACould meet >1 exclusion criterion (Supplement 1).īConcern for clinically relevant hypotension or escalation of vasopressor requirements, hyperkalemia, severe renal artery stenosis, pregnancy or breastfeeding, and, for ARB and DMX-200, severe liver disease or alanine transaminase or aspartate transaminase >5 times the upper limit of normal, known viral hepatitis, or hypersensitivity to repagermanium.ĬVia centralized computer program with balanced assignment based on the number of interventions per site.ĭReceiving respiratory or cardiovascular organ support.ĮAvailable later than ACE inhibitor and ARB interventions at a subset of sites.įThe primary analysis in the RAS domain is estimated from a model that adjusts for patient factors and randomization to other interventions all patients enrolled in the COVID-19 cohort with consent and follow-up are included.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |